L'association trastuzumab (Herceptin ®) - lapatinib (Tyverb ®) dans le traitement des cancers du sein : une approche thérapeutique prometteuse

Abstract : Currently, many women are concerned by breast cancer. However, thanks to the research three out of four people are cured. There are many breast cancers with various characteristics, that's why there are different treatments. Today, we try to use targeted therapies as much as possible. Trastuzumab (Hercpetin ®) and lapatinib (Tyverb ® ) are two targeted therapies. For best results, in some breast cancer, they can be used together. In this situation, pharmacist can assist each patient from the beginning to the end of their disease, with many advices.
Document type :
Master Thesis
Complete list of metadatas

Cited literature [59 references]  Display  Hide  Download

https://dumas.ccsd.cnrs.fr/dumas-01928144
Contributor : Ufr Santé Unicaen <>
Submitted on : Tuesday, November 20, 2018 - 12:55:25 PM
Last modification on : Wednesday, April 3, 2019 - 2:21:01 AM

File

DUVAL Mélanie.pdf
Files produced by the author(s)

Identifiers

  • HAL Id : dumas-01928144, version 1

Citation

Mélanie Duval. L'association trastuzumab (Herceptin ®) - lapatinib (Tyverb ®) dans le traitement des cancers du sein : une approche thérapeutique prometteuse. Sciences pharmaceutiques. 2017. ⟨dumas-01928144⟩

Share

Metrics

Record views

15

Files downloads

22